Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

BIZARRE: 63 - What They Never Told You

With Covid cases surging across Australia, will a fourth vaccine dose be required?

How effective would a second booster be? Who is eligible now? Why are third dose numbers lagging? Experts explain

The Guardian - AU

California could see coronavirus uptick this spring because of omicron subvariant BA.2

LOS ANGELES — Coronavirus cases are on the upswing worldwide, prompting some officials to warn that California could see increases this spring because of the omicron subvariant BA.2 even though cases so far have been modest.

Los Angeles Times

The Future of Boosters Is Somewhere Between Unnecessary and Urgent

Until there’s a universal coronavirus vaccine, the future of additional shots is a murky work in progress—but more rounds seem increasingly likely.

Businessweek

From analysis to the latest developments in health,
read the most diverse news in one place.

4th Covid jab to be offered this week as Spring booster rollout begins

The NHS said its Covid-19 vaccination programme will contact people when it is their turn to be vaccinated

Nottingham Post

Will AI turbocharge the hunt for new drugs?

Advocates point to the pandemic as proof of its value in healthcare even as critics dismiss its use in drug discovery as ‘hype’

Financial Times

Hyderabad cos get licence for Pfizer’s Covid pill

HYDERABAD: Apart from Hyderabad-based pharma major Aurobindo Pharma Limited, other city-based pharma players like Granules India Ltd, MSN Group and SMS Pharmaceuticals too have received licences from the UN-backed Medicines Patent Pool (MPP) to manufacture and supply a generic version of nirmatrelvir, a key component of Pfizer’s oral Covid-19 drug…

The Times of India

Big Pharma won't let the vaccine out

Waiving Covid vaccine patents would help poor countries fight the disease. Pharma giants won't let that happen

Salon

Read news from The Economist, FT, and more,
with one subscription

Maker Of Pfizer's COVID-19 Vaccine mRNA-Delivery Tech Sues Arbutus Biopharma: Reuters

Canada-based Acuitas Therapeutics Inc has sued Arbutus Biopharma Corporation (NASDAQ: ABUS) in Manhattan federal court, seeking to head off claims that the vaccine infringes Arbutus' patents,

Benzinga

Marjorie Taylor Greene condemns Covid boosters by claiming polio vaccine is only one jab – but it actually takes four

‘I think the question we all should ask is “when does it stop?” and “when are enough vaccines enough?”’ Greene said

The Independent UK

Like Pfizer, Moderna Seeks FDA Approval For Fourth COVID-19 Shot Or Second Booster Dose

Moderna Inc (NASDAQ: MRNA) has asked the FDA to authorize a

Benzinga

Moderna Seeks US Approval of Second Covid Booster

Moderna announced Thursday it had asked the United States drug regulator for emergency authorization for a second booster shot of the company's Covid-19 vaccine for all adults. The request to the US Food and Drug Administration (FDA) would "allow for a fourth dose of our #COVID19 vaccine in adults 18…

Asharq Al-Awsat

Moderna requests FDA approval for fourth COVID shot for adults

Moderna Inc. has filed for U.S. regulatory clearance of a second COVID-19 booster shot for all adults, covering significantly more people than Pfizer Inc. and BioNTech SE’s request earlier this week for a more limited emergency authorization for those over 65.

Tribune News Service

Moderna asks FDA to authorize additional booster shot for all adults

The request is much broader than Pfizer's, which sought to authorize a second booster for people over 65.

Axios

Vic strikes mRNA vaccine deal with Pfizer

Drug company Pfizer has agreed to increase collaboration with Victorian researchers working on mRNA vaccines.

AAP

Get all your
news in one place.

100's of premium titles.
One news app.

The Times of India

Aurobindo gets licence for supply of Pfizer’s Covid pill

HYDERABAD: Pharma major Aurobindo Pharma Limited has inked a sub-license agreement with the United Nations-backed public health organisation Medicines Patent Pool (MPP) for manufacturing and supplying a generic version of Pfizer’s oral Covid-19 treatment drug nirmatrelvir to 95 countries, including India.

ABC News

Anti-vaxxers are claiming an outbreak of Japanese encephalitis is really being caused by adverse reactions to Pfizer's vaccine. Here's why that's bunkum

Anti-vaxxers are once again using a Pfizer document to spread misinformation, this week claiming that Japanese encephalitis is a cover-up for adverse reactions to the company's vaccine.

The Hindu

19 firms in India to make Pfizer’s oral COVID-19 antiviral drug

They have signed sublicence agreements with United Nations-backed Medicines Patent Pool

Benzinga

35 Generic Drugmakers Sign To Manufacture Low-Cost Version Of Pfizer's COVID Pill

Thirty-five generic drugmakers will produce low-cost versions of Pfizer Inc's (NYSE:PFE) COVID-19 pill, Paxlovid, to expand supplies of the highly effective drug in lower-income regions. Pfizer struck a deal last year with the group to allow generic drugmakers to make the pills for 95 low- and middle-income countries, covering up to approximately 53% of the…

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

More than 30 companies to start making Pfizer's COVID pill

The U.N.-backed Medicines Patent Pool says that nearly three dozen companies worldwide will soon start making generic versions of Pfizer’s coronavirus pill

Benzinga

Health Canada Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years

Health Canada has approved Moderna Inc's (NASDAQ:MRNA) mRNA COVID-19 vaccine, Spikevax, two-dose series of 50 µg per dose to prevent COVID-19 in children aged six to11 years. The announcement follows the recent authorization of the Company's COVID-19 vaccine in the same age group in both Australia and the European Union. "Health Canada was…

Benzinga

Alnylam Hits Pfizer, Moderna With Patent Infringement Suits

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) has filed separate lawsuits in the Delaware federal court against Pfizer Inc (NYSE:PFE) and Moderna Inc (NASDAQ:MRNA), seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines. Alnylam said it was seeking compensation for the use of its lipid nanoparticles (LNP) technology that carries and delivers…

The Guardian - UK

GlaxoSmithKline says it will not start any new clinical trials in Russia

Pharma firm joins AstraZeneca and Pfizer in saying it will not enrol new patients into studies

Benzinga

Ionis Pharma Announces Publication Of Positive Donidalorsen Data For Angioedema Attacks

Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced the publication of Phase 2 data for donidalorsen in the New England Journal of Medicine (NEJM). Donidalorsen is an investigational antisense medicine under development for hereditary angioedema (HAE), a disorder characterized by recurrent episodes of severe swelling. In the Phase 2 study, donidalorsen demonstrated a 90% reduction in…

Axios

COVID boosters' short effectiveness window brings skepticism about 4th shot

Some experts are already skeptical that another shot is warranted for most people.

Los Angeles Times

Second COVID-19 booster shot does little to stop omicron, study finds

Israeli health care workers who were boosted with a fourth shot of COVID-19 vaccine at the height of the omicron wave were only marginally more protected against reinfection than their peers who had received three jabs of vaccine, researchers reported Wednesday.

1 … 62 63 64 65

People

Marjorie Taylor Greene

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations